Cite
HARVARD Citation
Randrian, V. et al. (2022). FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. Digestive and liver disease. 54 (7), pp. 857-863. [Online].